Lymphoma

Latest News

The agency submits complete response letters based on the enrollment status of confirmatory trials for odronextamab in follicular lymphoma and diffuse large B-cell lymphoma.
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and DLBCL

March 26th 2024

The agency submits complete response letters based on the enrollment status of confirmatory trials for odronextamab in follicular lymphoma and diffuse large B-cell lymphoma.

The regulatory agency sets a Prescription Drug User Fee Act date of August 13, 2024, for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma.
FDA Accepts Resubmitted BLA for Denileukin Diftitox in R/R CTCL

March 19th 2024

FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL
FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL

March 15th 2024

Treatment with brentuximab vedotin, lenalidomide, and rituximab yielded a progression-free survival benefit in the phase 3 ECHELON-3 trial.
Brentuximab Vedotin Combo Significantly Improves Survival in R/R DLBCL

March 12th 2024

Strategies must be framed for addressing racial and geographic disparities in access for CAR T-cell and bispecific antibody therapy, according to the study authors.
Geographic, Racial Disparities Exist in CAR T, Bispecific Access in DLBCL

March 12th 2024

Video Series
Video Interviews
Podcasts
The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.
Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma
Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast.
Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Latest CME Events & Activities

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News